Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche

  • Leukemia. 2024 May;38(5):936-946. doi: 10.1038/s41375-024-02226-6.
Susann Winter  1 ,  Katharina S Götze  2  3  4 ,  Judith S Hecker  2  3  5 ,  Klaus H Metzeler  2  6 ,  Borhane Guezguez  2  7 ,  Kevin Woods  2  7 ,  Hind Medyouf  2  8  9 ,  Alexander Schäffer  8 ,  Marc Schmitz  2  10  11 ,  Rebekka Wehner  2  10  11 ,  Ingmar Glauche  12 ,  Ingo Roeder  2  11  12 ,  Martina Rauner  13 ,  Lorenz C Hofbauer  #  14  15 ,  Uwe Platzbecker  #  16  17  18
Affiliations
  • 1. Department of Internal Medicine I, University Hospital Carl Gustav Carus, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • 2. German Cancer Consortium (DKTK), CHOICE Consortium, Partner Sites Dresden/Munich/Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • 3. Department of Medicine III, Technical University of Munich (TUM), School of Medicine and Health, Munich, Germany.
  • 4. German MDS Study Group (D-MDS), Leipzig, Germany.
  • 5. TranslaTUM, Center for Translational Cancer Research, Technical University of Munich (TUM), Munich, Germany.
  • 6. Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University of Leipzig Medical Center, Leipzig, Germany.
  • 7. Department of Hematology and Oncology, University Medical Center Mainz, Mainz, Germany.
  • 8. Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.
  • 9. Frankfurt Cancer Institute, Frankfurt am Main, Germany.
  • 10. Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • 11. National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • 12. Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • 13. Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III, and Center for Healthy Aging, University Medical Center, TU Dresden, Dresden, Germany.
  • 14. German Cancer Consortium (DKTK), CHOICE Consortium, Partner Sites Dresden/Munich/Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany. [email protected].
  • 15. Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III, and Center for Healthy Aging, University Medical Center, TU Dresden, Dresden, Germany. [email protected].
  • 16. German Cancer Consortium (DKTK), CHOICE Consortium, Partner Sites Dresden/Munich/Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany. [email protected].
  • 17. German MDS Study Group (D-MDS), Leipzig, Germany. [email protected].
  • 18. Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University of Leipzig Medical Center, Leipzig, Germany. [email protected].
  • # Contributed equally.
Abstract

Clonal hematopoiesis (CH) defines a premalignant state predominantly found in older persons that increases the risk of developing hematologic malignancies and age-related inflammatory diseases. However, the risk for malignant transformation or non-malignant disorders is variable and difficult to predict, and defining the clinical relevance of specific candidate driver mutations in individual carriers has proved to be challenging. In addition to the cell-intrinsic mechanisms, mutant cells rely on and alter cell-extrinsic factors from the bone marrow (BM) niche, which complicates the prediction of a mutant cell's fate in a shifting pre-malignant microenvironment. Therefore, identifying the insidious and potentially broad impact of driver mutations on supportive niches and immune function in CH aims to understand the subtle differences that enable driver mutations to yield different clinical outcomes. Here, we review the changes in the aging BM niche and the emerging evidence supporting the concept that CH can progressively alter components of the local BM microenvironment. These alterations may have profound implications for the functionality of the osteo-hematopoietic niche and overall bone health, consequently fostering a conducive environment for the continued development and progression of CH. We also provide an overview of the latest technology developments to study the spatiotemporal dependencies in the CH BM niche, ideally in the context of longitudinal studies following CH over time. Finally, we discuss aspects of CH carrier management in clinical practice, based on work from our group and Others.